However, the emergence of imatinib-resistant BCR-ABL in CML patients has called for the development of additional inhibitors and alternative strategies to sustain disease remission [15], [16], [17], [18]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.